Melanoma-restricted genes.

PubWeight™: 1.03‹?› | Rank: Top 15%

🔗 View Article (PMID 15488140)

Published in J Transl Med on October 15, 2004

Authors

Ena Wang, Monica C Panelli, Katia Zavaglia, Susanna Mandruzzato, Nan Hu, Phil R Taylor, Barbara Seliger, Paola Zanovello, Ralph S Freedman, Francesco M Marincola

Articles cited by this

Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97

Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86

High-fidelity mRNA amplification for gene profiling. Nat Biotechnol (2000) 6.97

Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest (2000) 4.16

Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet (2004) 3.78

B-RAF is a therapeutic target in melanoma. Oncogene (2004) 3.61

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05

Role of chemokines in the biology of natural killer cells. J Leukoc Biol (2002) 2.34

Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21

Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol (1992) 2.19

Advantages of mRNA amplification for microarray analysis. Biotechniques (2002) 2.00

S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem (2004) 1.94

Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol (2003) 1.80

Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol (2002) 1.74

Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J Interferon Cytokine Res (2002) 1.68

Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67

Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer (1998) 1.65

Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev (2003) 1.61

High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun (1999) 1.58

Convergence of the NF-kappaB and interferon signaling pathways in the regulation of antiviral defense and apoptosis. Ann N Y Acad Sci (2003) 1.55

Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol (2002) 1.55

Structure and function of IRF-7. J Interferon Cytokine Res (2002) 1.53

Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics (2004) 1.45

The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res (2004) 1.30

Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood (2004) 1.29

NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci (2003) 1.21

Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother (2003) 1.21

Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene (2004) 1.18

Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol (1996) 1.16

Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis (2003) 1.15

Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene (2003) 1.14

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol (1993) 1.14

Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Vet Pathol (2000) 1.10

Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer (1999) 1.07

Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother (1998) 1.06

Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol (2000) 1.03

Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes. Exp Dermatol (2003) 1.03

Active-specific immunization against melanoma: is the problem at the receiving end? Semin Cancer Biol (2003) 1.00

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol (1994) 1.00

T-cell recognition of self peptides as tumor rejection antigens. Immunol Res (1996) 0.95

IL-21 and IL-21 receptor: a new cytokine pathway modulates innate and adaptive immunity. Immunol Res (2003) 0.91

Short-term kinetics of tumor antigen expression in response to vaccination. J Immunol (2001) 0.91

sAPP as a regulator of dendrite motility and melanin release in epidermal melanocytes and melanoma cells. FASEB J (2003) 0.90

mRNA expression of tumor-associated antigens in melanoma tissues and cell lines. Exp Dermatol (2002) 0.88

Cytokine and tumor cell apoptosis inducing activity of mda-7/IL-24. Int Immunopharmacol (2004) 0.88

Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. Cancer Res (2004) 0.87

Interleukin-16 network in inflammation and allergy. Allergy Asthma Proc (2002) 0.87

Differentiation between merkel cell carcinoma and malignant melanoma: An immunohistochemical study. Dermatology (2000) 0.86

Identification of tumor antigens and T-cell epitopes, and its clinical application. Cancer Immunol Immunother (2003) 0.86

Serum neuron specific enolase: can it be a tumour marker for renal cell carcinoma? Int Urol Nephrol (1996) 0.85

cDNA arrays and the enigma of melanoma immune responsiveness. Cancer J (2001) 0.81

Chemotaxis of human CD4+ eosinophils. Int Arch Allergy Immunol (2001) 0.77

Elevated concentrations of gamma-enolase in renal cell tumors in rats: similarity to renal cell carcinoma in man. Urol Res (1996) 0.77

Identification of human tumor antigens recognized by T-cells and their use for immunotherapy. Int J Hematol (2003) 0.76

Articles by these authors

Prevalence and control of diabetes in Chinese adults. JAMA (2013) 11.73

Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol (2005) 9.27

A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15

Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09

Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol (2010) 4.62

Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev (2008) 4.36

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88

Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69

IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 3.69

Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 3.56

A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet (2010) 3.53

Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21

Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02

Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94

Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity (2013) 2.86

L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol (2003) 2.81

The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79

Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res (2007) 2.69

Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (2003) 2.65

IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 2.64

MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med (2010) 2.57

Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA (2003) 2.50

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A (2005) 2.49

MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48

Evidence of dysregulation of dendritic cells in primary HIV infection. Blood (2010) 2.39

BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 2.36

Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32

Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol (2005) 2.24

Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21

Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet (2002) 2.10

Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol (2007) 2.10

Lost in Translation: Obstacles to Translational Medicine. J Transl Med (2004) 2.03

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03

Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. Nat Genet (2012) 2.00

The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00

A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat (2011) 1.99

Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96

Gene expression profiling of cutaneous wound healing. J Transl Med (2007) 1.91

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90

Quantitative real-time PCR: a powerful ally in cancer research. Trends Mol Med (2003) 1.88

Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother (2012) 1.87

Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol (2007) 1.87

2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics (2002) 1.85

MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med (2009) 1.85

What's next in translational medicine? Clin Sci (Lond) (2007) 1.85

In support of descriptive studies; relevance to translational research. J Transl Med (2007) 1.82

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77

Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol (2002) 1.74

Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72

The dual role of IL-10. Trends Immunol (2003) 1.72

Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72

Allele-specific chromatin immunoprecipitation studies show genetic influence on chromatin state in human genome. PLoS Genet (2007) 1.71

Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci (2014) 1.69

Clonal persistence and evolution during a decade of recurrent melanoma. J Invest Dermatol (2006) 1.69

Next generation of immunotherapy for melanoma. J Clin Oncol (2008) 1.69

Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res (2005) 1.68

HIV testing among men who have sex with men in China: a systematic review and meta-analysis. AIDS Behav (2012) 1.67

Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67

A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res (2003) 1.63

The immunologic constant of rejection. Trends Immunol (2008) 1.62

Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res (2012) 1.61

Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology (2012) 1.61

Part I: Vaccines for solid tumours. Lancet Oncol (2004) 1.61

Obstacles and opportunities in translational research. Nat Med (2005) 1.59

The Fabrication of Nano-Particles in Aqueous Solution From Oxyfluoride Glass Ceramics by Thermal Induction and Corrosion Treatment. Nanoscale Res Lett (2008) 1.59